TWi Biotechnology, Inc.
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial fo… Read more
Market Cap & Net Worth: TWi Biotechnology, Inc. (6610)
TWi Biotechnology, Inc. (TWO:6610) has a market capitalization of $124.32 Million (NT$4.11 Billion) as of March 19, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #24205 globally and #1459 in its home market, demonstrating a -3.58% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying TWi Biotechnology, Inc.'s stock price NT$20.20 by its total outstanding shares 203629395 (203.63 Million).
TWi Biotechnology, Inc. Market Cap History: 2026 to 2026
TWi Biotechnology, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $124.32 Million to $124.32 Million (0.00% CAGR).
TWi Biotechnology, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how TWi Biotechnology, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6610 by Market Capitalization
Companies near TWi Biotechnology, Inc. in the global market cap rankings as of March 19, 2026.
Key companies related to TWi Biotechnology, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
TWi Biotechnology, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, TWi Biotechnology, Inc.'s market cap moved from $124.32 Million to $ 124.32 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$124.32 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of TWi Biotechnology, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $124.32 Million USD |
| MoneyControl | $124.32 Million USD |
| MarketWatch | $124.32 Million USD |
| marketcap.company | $124.32 Million USD |
| Reuters | $124.32 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.